Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) (Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF), Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF)) CEO James Graham sits down with Proactive’s Jonathan Jackson to discuss the completion of dosing of its latest cohort in the Phase 1/2 UTI/Urosepsis clinical trial. This trial investigates the effectiveness of RECCE® 327 (R327) at rapid infusion rates. The company successfully administered its highest dosage yet, delivering 4,000mg of R327 over 20 minutes to six participants.
Administering antibiotics through rapid intravenous infusions has shown to be safe and effective, improving patient care, reducing wait times and decreasing nursing workloads globally.
An independent safety committee will review the cohort data with preliminary results anticipated in the coming weeks. The trial has already identified the minimum inhibitory concentration (MIC) activity against bacteria in clinical samples, assisting in dose optimisation for regulatory purposes.
Graham highlighted the achievement of a new milestone by administering the highest dosage to date, underscoring its significance in advancing R327 as a potential treatment for UTI/Urosepsis. Data from this trial will inform the design of a Phase 2 efficacy trial, which aims to establish R327 as a frontline treatment. Full efficacy data from the trial will be available upon its completion according to the study protocol.